Health & Biotech
IHL share price climbs before debuting on S&P/ASX 300 index
Health & Biotech
INOVIQ is carving itself a healthy share of the multi-billion dollar medical diagnostics market
Health & Biotech
Check Up: As the pandemic winds down, what’s happening with Covid focused biotechs?
Health & Biotech
PharmAust recruits first dog patient in the US, aims to close out Phase 2 canine trial faster
Health & Biotech
This ASX stock is watching you while you sleep… because it could point to Parkinson’s disease
Health & Biotech
ASX Health Stocks: China likes Uscom device, includes it in national emergency guidelines
Health & Biotech
Excitement builds as Prescient achieves key milestones in personalised cancer treatment
Health & Biotech
ASX Health Stocks: Tissue Repairs granted second patent in US; Clarity to start Phase 2 recruitment
Health & Biotech
ASX Health Stocks: Pharmaxis gets $5m to fund groundbreaking collaboration study of lead drug PXS‐4728
Health & Biotech
Opyl prepares to launch Opin into the global $4.7 billion clinical trial recruitment market
Health & Biotech
Nutritional Growth Solutions reaches healthy heights in H1 FY22, future growth looks strong
Health & Biotech
EZZ’s remained ‘disciplined’ to deliver successful end to FY22
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.